Michael Augenbraun, MD; Joseph Feldman, DrPH; Keith Chirgwin, MD; Jonathan Zenilman, MD; Lorraine Clarke, PhD; Jack DeHovitz, MD, MPH; Sheldon Landesman, MD; Howard Minkoff, MD
To compare the prevalence of genital herpes simplex virus type 2 (HSV-2) shedding in human immunodeficiency virus (HIV)-seropositive women and HIV-seronegative women.
A major inner-city medical center.
106 women who were HIV-seropositive and HSV-2-seropositive and 70 women who were HIV-seronegative and HSV-2-seropositive were enrolled from various primary care settings.
Herpes simplex virus type 2 antibody determinations were done for all patients. Regardless of symptoms, vulvar and cervical HSV cultures were obtained from all HIV-seropositive women and from a randomly selected subgroup of HIV-seronegative women.
The prevalence of HSV-2 shedding was nearly four times greater in HIV-seropositive than in HIV-seronegative women (13.2% compared with 3.6%; P = 0.04; odds ratio, 4.1 [95% CI, 1.0 to 27.4]) when the serum antibody for HSV-2 was present. Seventy-nine percent of viral shedding among HIV-seropositive women was asymptomatic. Overall viral shedding increased significantly as the CD4 cell count decreased.
Women with HIV infection, particularly those with low CD4 cell counts, shed HSV-2 from the vulva and cervix more commonly than women not infected with HIV. Most of this shedding is asymptomatic.
Augenbraun M, Feldman J, Chirgwin K, et al. Increased Genital Shedding of Herpes Simplex Virus Type 2 in HIV-Seropositive Women. Ann Intern Med. 1995;123:845–847. doi: 10.7326/0003-4819-123-11-199512010-00006
Download citation file:
Published: Ann Intern Med. 1995;123(11):845-847.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use